Cost considerations for adoption of diabetes technology are pervasive: A qualitative study of persons living with type 1 diabetes and their families

被引:24
作者
Addala, Ananta [1 ]
Suttiratana, Sakinah C. [2 ]
Wong, Jessie J. [1 ]
Lanning, Monica S. [1 ]
Barnard, Katharine D. [3 ]
Weissberg-Benchell, Jill [4 ]
Laffel, Lori M. [5 ,6 ]
Hood, Korey K. [1 ]
Naranjo, Diana [1 ]
机构
[1] Stanford Univ, Div Endocrinol, Dept Pediat, Stanford, CA 94305 USA
[2] Yale Sch Publ Hlth, Dept Chron Dis Epidmiol, New Haven, CT USA
[3] Bournemouth Univ, Bournemouth, Dorset, England
[4] Northwestern Univ, Feinberg Sch Med, Ann & Robert H Lurie Childrens Hosp, Dept Psychiat & Behav Sci, Chicago, IL 60611 USA
[5] Harvard Med Sch, Boston, MA 02115 USA
[6] Joslin Diabet Ctr, Boston, MA USA
关键词
qualitative research; automated insulin delivery; diabetes technology; psychosocial barriers; SOCIAL-ECOLOGICAL MODEL; MANAGEMENT; SYSTEM; TRIAL;
D O I
10.1111/dme.14575
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Cost is a major consideration in the uptake and continued use of diabetes technology. With increasing use of automated insulin delivery systems, it is important to understand the specific cost-related barriers to technology adoption. In this qualitative analysis, we were interested in understanding and examining the decision-making process around cost and diabetes technology use. Materials and Methods Four raters coded transcripts of four stakeholder groups using inductive coding for each stakeholder group to establish relevant themes/nodes. We applied the Social Ecological Model in the interpretation of five thematic levels of cost. Results We identified five thematic levels of cost: policy, organizational, insurance, interpersonal and individual. Equitable diabetes technology access was an important policy-level theme. The insurance-level theme had multiple subthemes which predominantly carried a negative valence. Participants also emphasized the psychosocial burden of cost specifically identifying diabetes costs to their families, the guilt of diabetes related costs, and frustration in the time and involvement required to ensure insurance coverage. Conclusion We found broad consensus in how cost is experienced by stakeholder groups. Cost considerations for diabetes technology uptake extended beyond finances to include time, cost to society, morality and interpersonal relationships. Cost also reflected an important moral principle tied to the shared desire for equitable access to diabetes technology. Knowledge of these considerations can help clinicians and researchers promote equitable device uptake while anticipating barriers for all persons living with type 1 diabetes and their families.
引用
收藏
页数:15
相关论文
共 33 条
  • [1] Psychosocial and Human Factors During a Trial of a Hybrid Closed Loop System for Type 1 Diabetes Management
    Adams, Rebecca N.
    Tanenbaum, Molly L.
    Hanes, Sarah J.
    Ambrosino, Jodie M.
    Ly, Trang T.
    Maahs, David M.
    Naranjo, Diana
    Walders-Abramson, Natalie
    Weinzimer, Stuart A.
    Buckingham, Bruce A.
    Hood, Korey K.
    [J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2018, 20 (10) : 648 - 653
  • [2] A Decade of Disparities in Diabetes Technology Use and HbA1c in Pediatric Type 1 Diabetes: A Transatlantic Comparison
    Addala, Ananta
    Auzanneau, Marie
    Miller, Kellee
    Maier, Werner
    Foster, Nicole
    Kapellen, Thomas
    Walker, Ashby
    Rosenbauer, Joachim
    Maahs, David M.
    Holl, Reinhard W.
    [J]. DIABETES CARE, 2021, 44 (01) : 133 - 140
  • [3] Uninterrupted continuous glucose monitoring access is associated with a decrease inHbA1cin youth with type 1 diabetes and public insurance
    Addala, Ananta
    Maahs, David M.
    Scheinker, David
    Chertow, Solana
    Leverenz, Brianna
    Prahalad, Priya
    [J]. PEDIATRIC DIABETES, 2020, 21 (07) : 1301 - 1309
  • [4] Racial-Ethnic Inequity in Young Adults With Type 1 Diabetes
    Agarwal, Shivani
    Kanapka, Lauren G.
    Raymond, Jennifer K.
    Walker, Ashby
    Gerard-Gonzalez, Andrea
    Kruger, Davida
    Redondo, Maria J.
    Rickels, Michael R.
    Shah, Viral N.
    Butler, Ashley
    Gonzalez, Jeffrey
    Verdejo, Alandra S.
    Gal, Robin L.
    Willi, Steven
    Long, Judith A.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2020, 105 (08) : E2960 - E2969
  • [5] Current Eligibility Requirements for Continuous Glucose Monitoring Coverage Are Harmful, Costly, and Unjustified
    Anderson, John E.
    Gavin, James R., III
    Kruger, Davida F.
    [J]. DIABETES TECHNOLOGY & THERAPEUTICS, 2020, 22 (03) : 169 - 173
  • [6] [Anonymous], 2009, INTERVIEWS LEARNING
  • [7] What's distressing about having type 1 diabetes? A qualitative study of young adults' perspectives
    Balfe, Myles
    Doyle, Frank
    Smith, Diarmuid
    Sreenan, Seamus
    Brugha, Ruairi
    Hevey, David
    Conroy, Ronan
    [J]. BMC ENDOCRINE DISORDERS, 2013, 13
  • [8] Barnard Katharine D, 2018, J Diabetes Sci Technol, V12, P1227, DOI 10.1177/1932296818788872
  • [9] Safety of a Hybrid Closed-Loop Insulin Delivery System in Patients With Type 1 Diabetes
    Bergenstal, Richard M.
    Garg, Satish
    Weinzimer, Stuart A.
    Buckingham, Bruce A.
    Bode, Bruce W.
    Tamborlane, William V.
    Kaufman, Francine R.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 316 (13): : 1407 - 1408
  • [10] Bronfenbrenner U., 1979, ECOLOGY HUMAN DEV, DOI DOI 10.1191/1478088706QP063OA